Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) have been given a consensus recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company.

BIOVF has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on shares of Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They issued a “buy” rating for the company. Danske downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, February 19th. BNP Paribas Exane upgraded shares of Swedish Orphan Biovitrum to an “outperform” rating in a research report on Tuesday, February 10th. Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, February 24th. Finally, Zacks Research raised Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, May 7th.

Swedish Orphan Biovitrum Price Performance

BIOVF stock opened at $47.48 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.70 and a quick ratio of 0.47. The firm has a market capitalization of $16.90 billion, a P/E ratio of 158.25 and a beta of 0.36. The company’s 50 day simple moving average is $43.38 and its 200-day simple moving average is $39.06. Swedish Orphan Biovitrum has a 52-week low of $27.06 and a 52-week high of $47.48.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.07. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 16.66%. The firm had revenue of $755.76 million for the quarter, compared to the consensus estimate of $749.76 million. As a group, equities research analysts anticipate that Swedish Orphan Biovitrum will post 2.22 EPS for the current year.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.